ABOS Stock — Acumen Pharmaceuticals Inc.: Cash, EV, Pipeline

Share price

$2.65

Market cap

$191.6M

Cash

$110.2M

Enterprise value

$113.0M

Balance sheet

Cash	$110.2M
Debt	$31.6M
Net cash	$78.6M
Enterprise value	$113.0M
Basic shares	72.3M shares
Fully diluted shares	101.8M shares
Fully diluted market cap	$269.9M
Cash per share	$1.52

Cash figures as of 2026-06-30. Database snapshot: 2026-09-21.

Price history

Loading ABOS daily closes…

Loading price history…

Upcoming catalysts

Expected	Drug	Phase	Indication	Mgmt guide
Nov 12 - Dec 24	sabirnetug	Phase 2	Alzheimer Disease	—

Estimated readout windows: registry primary-completion date + 6-12 weeks. Windows already open are shown from "Now". Drug names link to ClinicalTrials.gov.

Full readout calendar →

Pipeline assets

sabirnetug

Phase 2 · Active Modality: monoclonal antibody (IgG2)

Aliases ACU193

Target amyloid-beta oligomers (AβOs)

Partnerships Halozyme, Inc.: non-exclusive license to Halozyme drug-delivery technology for a subcutaneous formulation of sabirnetug (seven-figure upfront paid Jan 2024; development/commercial milestones; single-digit royalties on worldwide net sales); Lonza Sales AG: non-exclusive manufacturing license (glutamine synthetase expression system), 1.0M CHF upfront, <1% to low-single-digit royalties

Indications

Alzheimer's disease (early AD: mild cognitive impairment or mild dementia due to AD) (Phase 2)

Catalysts

— late 2026

Status note Sole clinical-stage product candidate. FDA granted Fast Track designation to ACU193 in October 2022. Phase 1 subcutaneous formulation study in healthy volunteers completed March 2025; supports further development as more convenient dosing option.

ACU301

Preclinical · Active

Target amyloid-beta oligomers (AβOs)

Partnerships JCR Pharmaceuticals: collaboration, option and license agreement for Aβ oligomer-targeted EBD candidates (upfront paid 2025; $9.25M option exercise paid June 2026; up to $40M development + $515M sales milestones; single-digit royalties)

Indications

Alzheimer's disease (Preclinical)

Catalysts

— mid-2027

Status note One of two EBD (Enhanced Brain Delivery) development candidates nominated June 2026 and licensed under the JCR collaboration. Preclinical data reported March 2026.

ACU401

Preclinical · Active

Target amyloid-beta oligomers (AβOs)

Partnerships JCR Pharmaceuticals: collaboration, option and license agreement for Aβ oligomer-targeted EBD candidates (upfront paid 2025; $9.25M option exercise paid June 2026; up to $40M development + $515M sales milestones; single-digit royalties)

Indications

Alzheimer's disease (Preclinical)

Catalysts

— mid-2027

Status note One of two EBD (Enhanced Brain Delivery) development candidates nominated June 2026 and licensed under the JCR collaboration. Preclinical data reported March 2026.

Per-asset detail extracted from the 10-Q filed 2026-08-12. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.

Pipeline

Lead drug	sabirnetug
Lead indication	Alzheimer Disease
Lead phase	Phase 2
Active trials	1

Active clinical trials

Trial	Phase	Status	Role	Sponsor	BP	Condition(s)	Mgmt guide
NCT06335173	Phase 2	Active, not recruiting	Sponsor	Acumen Pharmaceuticals	—	Alzheimer Disease	—

Sponsor-matched active trials from ClinicalTrials.gov (1 as sponsor, 0 as collaborator); "Sponsor" = company is the lead sponsor, "Collaborator" = company is a collaborator. The BP column flags big-pharma involvement as lead sponsor or collaborator (excluding the company itself). The Mgmt guide column shows what management guided for readout timing when a guided program matches the trial (hover for the quote, click for the source). Trial listings are not a company pipeline slide.

View all 1 active trials for Acumen Pharmaceuticals on ClinicalTrials.gov

Institutional holders

Fund	Shares	Q/Q change	% of portfolio	Filing
ADAR1 Capital Management	2,111,334	-45,000	0.26%	2026-08-14
Ikarian Capital	1,053,797	no change	0.46%	2026-08-14

Institutional holder positions from 13F filings. Q/Q change is vs the prior quarter's filing; % of portfolio is the fund's own reported portfolio weight.

ABOS — Acumen Pharmaceuticals Inc.

Balance sheet

Price history

Upcoming catalysts

Pipeline assets

Pipeline

Active clinical trials

Institutional holders